Antengene received approval from the Chinese NMPA to conduct the trial. Credit: Arek Socha from Pixabay.

Antengene is set to begin the Phase I/II clinical trial of ATG-016 (eltanexor) monotherapy in patients with intermediate and higher risk myelodysplastic syndrome (MDS).

The latest development comes after the company received approval from the Chinese National Medical Products Administration (NMPA) to conduct the trial.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This is in accordance with the Revised International Prognostic Scoring System (IPSS-R) after the hypomethylating agents (HMA) based therapy failed.

MDS is a heterogeneous group of clonal disorders of the bone marrow hematopoietic stem cells (HPSCs).

It is characterised by ineffective hematopoiesis with peripheral blood cytopenia and an increased risk for developing acute myeloid leukaemia (AML).

The single-arm, open-label clinical study will analyse the pharmacokinetics, safety and efficacy of ATG-016 monotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Antengene founder, chairman and CEO Dr Jay Mei said: “The approval of the ATG-016 clinical trial demonstrates the efficient execution of the Antengene R&D team and is also the first clinical trial approval obtained by Antengene in mainland China after its listing.”

“As a second-generation orally available SINE compound, ATG-016 can reduce the blood-brain barrier penetration, thereby representing a broader therapeutic window with potentially less adverse events and better drug tolerability.”

The selective inhibitor of nuclear export (SINE) compound, ATG-016, has lower blood-brain barrier penetration and broader therapeutic window as compared to the first-generation SINE compound.

This permits more frequent dosing and a longer period of exposure at higher levels with better tolerability.

The company anticipates developing ATG-016 for cancers with high prevalence in the Asia-Pacific region (such as KRAS-mutant solid tumours) and virus infection-related malignancies (such as nasopharyngeal carcinoma).